A Revolutionary Approach to Cancer Treatment


Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefit to patients. Jounce utilizes its Translational Science Platform to first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.


Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

April 20, 2017
Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors

March 31, 2017
Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

March 22, 2017
Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Cary Pfeffer, M.D.
Partner

Perry Karsen
Venture Partner

Robert Kamen, Ph.D.
Entrepreneur-in-Residence